January 2011
119
Jꢂ6.9, 4.6 Hz, H-1ꢅ), 7.03 (1H, s, H-3), 7.18 (1H, s, H-6), 7.18 (1H, s, H-7),
ring for 12 h at room temperature, 1 M HCl (3 ml) was added for neutraliza-
12.4 (1H, s, OH-5), 12.6 (1H, s, OH-8).
tion and extracted with CHCl (10 ml), which was dried and evaporated in
3
Acetylshikonin (3) Red purple solid. ESI-MS (positive mode) m/z: 353 vacuo. The residue was dissolved in MeOH (1 ml) and subjected to reversed-
ꢀ
1
[
2
MꢀNa] , H-NMR (in CDCl ) d: 1.57 (3H, s, H-6ꢅ), 1.68 (3H, s, H-5ꢅ), phase LC/ESI-MS analysis as described above to check the achievement of
3
.13 (3H, s, H-2ꢁ), 2.46 (1H, m, H-2ꢅ), 2.60 (1H, m, H-2ꢅ), 5.11 (1H, t, saponification of 9. Subsequently, the saponificate of 9 was subjected to chi-
Jꢂ7.5 Hz, H-3ꢅ), 6.01 (1H, dd, Jꢂ6.9, 5.2 Hz, H-1ꢅ), 6.98 (1H, s, H-3), 7.18 ral-phase HPLC analysis to determine the ratio of shikonin to alkannin on
(1H, s, H-6), 7.18 (1H, s, H-7), 12.4 (1H, s, OH-5), 12.4 (1H, s, OH-8).
the peak areas of both compounds. For the chiral column, a Chiralcel-OJ-H
Propionylshikonin (4) Red purple solid. ESI-MS (positive mode) m/z: column (4.6 mm i.d.ꢃ250 mm, Daicel Chemical Industry, Osaka, Japan) was
ꢀ
1
3
5
67 [MꢀNa] , H-NMR (in CDCl ) d: 1.57 (3H, s, H-6ꢅ), 1.68 (3H, s, H- used at 40 °C. For the mobile phase, n-hexane/2-propanol/acetic acid
3
ꢅ), 2.40 (1H, d, Jꢂ7.7 Hz, H-2ꢁ), 2.41 (1H, d, Jꢂ7.7 Hz, H-2ꢁ), 2.48 (1H, (95 : 5 : 0.3, v/v) was used. The flow rate was 1.0 ml/min. The UV absorption
m, H-2ꢅ), 2.59 (1H, m, H-2ꢅ), 5.11 (1H, t, Jꢂ9.4 Hz, H-3ꢅ), 6.02 (1H, dd, was recorded at 515 nm on PDA. The retention times of shikonin and alkan-
Jꢂ6.3, 4.6 Hz, H-1ꢅ), 6.97 (1H, s, H-3), 7.18 (1H, s, H-6), 7.18 (1H, s, H-7),
nin were 12.3 min and 14.7 min, respectively.
1
2.42 (1H, s, OH-5), 12.4 (1H, s, OH-8).
Isobutyrylshikonin (5) Red purple solid. ESI-MS (positive mode) m/z: References
ꢀ
1
3
81 [MꢀNa] , H-NMR (in CDCl ) d: 1.20 (3H, d, Jꢂ6.8 Hz, H-3ꢁ), 1.20
1) Papageorgiou V. P., Assimopoulou A. N., Couladouros E. A., Hep-
worth D., Nicolau K. C., Angew. Chem. Int. Ed., 38, 271—300 (1999).
2) Brockmann H., Justus Liebigs Ann. Chem., 521, 1—47 (1936).
3) Morimoto I., Hirata Y., Tetrahedron Lett., 31, 3677—3680 (1966).
4) Hisamichi S., Yoshizaki F., Shoyakugaku Zasshi, 36, 154—159 (1982).
5) Cho M. H., Paik Y, S., Hahn T. R., Arch. Pharm. Res., 22, 414—416
(1999).
3
(
3H, d, Jꢂ6.8 Hz, H-4ꢁ), 1.58 (3H, s, H-6ꢅ), 1.68 (3H, s, H-5ꢅ), 2.48 (1H, m,
H-2ꢅ), 2.60 (1H, m, H-2ꢅ), 2.61 (1H, m, H-2ꢁ), 5.11 (1H, t, Jꢂ7.4 Hz, H-3ꢅ),
.01 (1H, dd, Jꢂ7.4, 4.6 Hz, H-1ꢅ), 6.97 (1H, s, H-3), 7.18 (1H, s, H-6), 7.18
6
(1H, s, H-7), 12.43 (1H, s, OH-5), 12.43 (1H, s, OH-8).
b,b-Dimethylacryloylshikonin (6) Red purple solid. ESI-MS (positive
ꢀ
1
mode) m/z: 393 [MꢀNa] , H-NMR (in CDCl ) d: 1.57 (3H, s, H-6ꢅ), 1.68
3
(3H, s, H-5ꢅ), 1.93 (3H, s, H-5ꢁ), 2.15 (3H, s, H-4ꢁ), 2.48 (1H, m, H-2ꢅ),
6) Morimoto I., Kishi T., Ikegami S., Hirata Y., Tetrahedron Lett., 52
4737—4739 (1965).
7) Kyogoku K., Terayama H., Tachi Y., Suzuki T., Komatsu M., Shoyaku-
gaku Zasshi, 27, 24—30 (1973).
2
6
.60 (1H, m, H-2ꢅ), 5.14 (1H, dd, Jꢂ6.9, 5.7 Hz, H-3ꢅ), 5.78, (1H, s, H-2ꢁ),
.00 (1H, dd, Jꢂ6.9, 5.8 Hz, H-1ꢅ), 6.97 (1H, s, H-3), 7.18 (1H, s, H-6), 7.18
(1H, s, H-7), 12.43 (1H, s, OH-5), 12.43 (1H, s, OH-8).
Isovalerylshikonin (7) Red purple solid. ESI-MS (positive mode) m/z:
8) Papageorgiou V. P., Assimopoulou A. N., Ballis A. C., Curr. Med.
Chem., 15, 3248—3267 (2008).
9) Li C., Fukushi Y., Kawabada J., Tahara S., Mizutani J., Uyeda I., J.
Pesticide Sci., 23, 54—57 (1998).
ꢀ
1
3
(
95 [MꢀNa] , H-NMR (in CDCl ) d: 0.96 (3H, d, Jꢂ2.3 Hz, H-4ꢁ), 0.97
3
3H, d, Jꢂ2.3 Hz, H-5ꢁ), 2.12 (1H, m, H-3ꢁ), 2.26 (2H, m, H-2ꢁ), 1.59 (3H,
s, H-6ꢅ), 1.68 (3H, s, H-5ꢅ), 2.45 (1H, m, H-2ꢅ), 2.59 (1H, m, H-2ꢅ), 5.12
(
1H, t, Jꢂ6.3 Hz, H-3ꢅ), 6.03 (1H, m, H-1ꢅ), 6.98 (1H, s, H-3), 7.18 (1H, s, 10) Tanaka Y., Odani T., Kanaya T., Shoyakugaku Zasshi, 28, 173—178
H-6), 7.18 (1H, s, H-7), 12.42 (1H, s, OH-5), 12.42 (1H, s, OH-8).
(1974).
a-Methylbutyrylshikonin (8) Red purple solid. ESI-MS (positive
11) Sankawa U., Ebizuka Y., Miyazaki T., Isomura Y., Otsuka H., Shibata
S., Inomata M., Fukuoka F., Chem. Pharm. Bull., 25, 2392—2395
(1977).
ꢀ
1
mode) m/z: 395 [MꢀNa] , H-NMR (in CDCl ) d: 0.92 (3H, t, Jꢂ7.5 Hz,
3
H-4ꢁ), 1.16 (3H, d, Jꢂ6.9 Hz, H-5ꢁ), 1.52 (1H, m, H-3ꢁ), 1.58 (3H, s, H-6ꢅ),
1
2
6
1
.68 (3H, s, H-5ꢅ), 1.70 (1H, m, H-3ꢁ), 2.45 (1H, m, H-2ꢅ), 2.46 (1H, m, H- 12) Hashimoto S., Xu M., Masuda Y., Aiuchi T., Nakajo S., Cao J.,
ꢁ), 2.59 (1H, m, H-2ꢅ), 5.12 (1H, t, Jꢂ6.3 Hz, H-3ꢅ), 6.03 (1H, m, H-1ꢅ),
.98 (1H, s, H-3), 7.18 (1H, s, H-6), 7.18 (1H, s, H-7), 12.42 (1H, s, OH-5),
Miyakosi M., Ida Y., Nakaya K., J. Biochem., 125, 17—23 (1999).
13) Ahn B. Z., Baik K. U., Kweon G. R., Lim K., Hwang B. D., J. Med.
Chem., 38, 1044—1047 (1995).
2.42 (1H, s, OH-8).
Tigloylshikonin (9) Red purple solid. IR (KBr) n
ꢄ1
cm : 1715, 1610, 14) Xuan Y., Hu X., Cancer Lett., 274, 233—242 (2009).
455, 760. ESI-MS (positive mode) m/z: 393 [MꢀNa] , HR-ESI-MS (posi- 15) Wang W., Dai M., Zhu C., Zhang J., Lin L., Ding J., Duan W., Bioorg.
max
ꢀ
1
ꢀ
tive mode) m/z: 371.14968 [MꢀH] (Calcd for C H O , 371.14946).
Med. Chem. Lett., 19, 735—737 (2009).
2
1
23
6
UV–Vis. l
(MeOH) nm (log e): 560 (3.6), 515.5 (3.8), 485 (3.6), 275.5 16) Noda N., Kogetsu H., Kawasaki T., Miyahara K., Phytochemistry, 31,
max
1
(
3.9). H-NMR (CDCl ) d: 1.57 (3H, s, H-6ꢅ), 1.68 (3H, s, H-5ꢅ), 1.83 (3H,
2761—2766 (1992).
3
d, Jꢂ8.0 Hz, H-4ꢁ), 1.86 (3H, s, H-5ꢁ), 2.53 (1H, m, H-2ꢅ), 2.64 (1H, m, H-
ꢅ), 5.14 (1H, t, Jꢂ8.0 Hz, H-3ꢅ), 6.04 (1H, dd, Jꢂ6.3, 5.1 Hz, H-1ꢅ), 6.95
1H, s, H-3), 6.97 (1H, m, H-3ꢁ) 7.18 (1H, s, H-6), 7.18 (1H, s, H-7), 12.39
17) Alvarez-Garcia R., Torres-Valencea J. M., Roman L. U., Hernandez J.
D., Cerda-Gracia-Rojas C. M., Joseph-Nathan P., Phytochemistry, 66,
639—642 (2005).
2
(
(
(
1
6
1
3
1H, s, OH-5), 12.43 (1H, s, OH-8), C-NMR (CDCl ) d: 12.2 (C-4ꢁ), 14.6 18) Ikeda Y., Ihida N., Fukuya C., Yokoyama K., Tabata M., Fukui H.,
3
C-5ꢁ), 18.1 (C-5ꢅ), 25.9 (C-6ꢅ), 33.0 (C-2ꢅ), 69.6 (C-1ꢅ), 111.7 (C-10),
11.9 (C-9), 117.9 (C-3ꢅ), 128.3 (C-2ꢁ), 131.5 (C-3), 132.6 (C-7), 132.8 (C-
), 136.1 (C-4ꢅ), 138.6 (C-3ꢁ), 149.0 (C-2), 166.5 (C-5), 166.8 (C-8), 167.1
C-1ꢁ), 177.4 (C-1), 178.9 (C-4).
Honda G., Chem. Pharm. Bull., 39, 2351—2352 (1991).
19) Afzal M., Tofeeq M., J. Chem. Soc. Perkin Trans. 1, 14, 1334 (1975).
20) Papageorgiou V. P., Digenis G. A., Planta Med., 39, 81—84 (1980).
21) Albreht A., Vovk I., Simonovska B., Srbinoska M., J. Chromatgr. A,
1216, 3156—3162 (2009).
(
Chiral Analysis of the Saponificates of 9 Chiral analysis was based on
18)
the manner reported previously. Briefly, the purified 9 (0.5 mg) was dis- 22) Majima R., Kuroda C., Acta Phytochim., 1, 43—65 (1922).
solved in MeOH (1 ml), and to this 1 M NaOH (3 ml) was added. After stir-